


replication that could be administered perorally.

Compounds that exhibit anti-RSV activity are disclosed in WO-2011/163518, WO-2013/096681 and WO-2013/158776.


5

Summary

The present disclosure, in one aspect, relates to compounds of formula (I-a) and formula (I-b), including any stereochemically isomeric form thereof, wherein



(I-a)



(I-b)

10 n is an integer 0, 1 or 2;

X is CH₂, O, CH₂O or NR⁴, wherein R⁴ is hydrogen, C₁₋₄alkyl or benzyl;

Z is CH₂, O or NR⁴, wherein R⁴ is hydrogen, C₁₋₄alkyl or benzyl;

and at least one of X or Z is CH₂;

R¹ is hydrogen, hydroxy, C₁₋₄alkyl, amino, mono- or di(C₁₋₄alkyl)amino, or Heterocyclyl¹;

15 Heterocyclyl¹ is azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl; wherein each Heterocyclyl¹ is optionally substituted with one or two substituents selected from C₁₋₄alkyl, hydroxy, halo, trifluoromethyl, C₁₋₄alkyloxy-carbonyl, amino, C₁₋₄alkylaminocarbonyl, or C₁₋₄alkylsulfonyl;

20 R² is phenyl-(CO)- wherein the phenyl is substituted with one or two substituents each independently selected from hydrogen, halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkyloxy, or C₁₋₄alkylsulfonylamino;

25 or R² is a bicyclic heterocycle selected from cinnolinyl, quinazolinyl, or quinoxalinyl, wherein said bicyclic heterocycle is substituted with one or two substituents each independently selected from hydrogen, halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkyloxy, and C₁₋₄alkylsulfonylamino; and

R³ is hydrogen, C₁₋₆alkyl, hydroxy, or halo;

or a pharmaceutically acceptable acid addition salt thereof.

30 The present disclosure, in another aspect, relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as defined herein.

The present disclosure, in another aspect, relates to a process for preparing a pharmaceutical composition as defined herein wherein a therapeutically active amount of a compound as defined herein is intimately mixed with a pharmaceutically acceptable carrier.

- 5 The present disclosure, in another aspect, relates to a compound as defined herein for use as a medicine.

- 10 The present disclosure, in another aspect, relates to a compound as defined herein, or a pharmaceutical composition as defined herein for use in the treatment of a respiratory syncytial virus infection.

As used in the foregoing definitions:

- halo is generic to fluoro, chloro, bromo and iodo;
- C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1
15 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; and
- (CO) or (C=O) stands for carbonyl.